Baclofen, a new antispastic drug. A controlled, multicenter trial in patients with multiple sclerosis, Arch Neurol, vol.34, pp.422-430, 1997. ,
Van der Kleijn E. Plasma and urinary excretion kinetics of oral baclofen in healthy subjects, Eur J Clin Pharmacol, vol.37, pp.181-185, 1989. ,
Van der Kleijn E. Pharmacokinetics of baclofen in spastic patients receiving multiple oral doses, Pharm. Weekbl Sci, vol.12, pp.71-75, 1990. ,
Clinical and pharmacokinetic aspects of high dose oral baclofen therapy, J Am Paraplegia Soc, vol.15, pp.211-217, 1992. ,
A randomized dose escalation study of intravenous Baclofen in healthy volunteers: clinical tolerance and pharmacokinetics, vol.9, pp.743-50, 2017. ,
A pilot study assessing pharmacokinetics and tolerability of oral and intravenous baclofen in healthy adult volunteers, J Child Neurol, vol.30, pp.37-41, 2015. ,
Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study, Lancet, vol.370, pp.61814-61819, 2007. ,
Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study, Alcohol Alcohol, vol.37, pp.504-512, 2002. ,
Efficacy and safety of baclofen for alcohol dependence: a randomized, doubleblind, placebo-controlled trial, Alcohol Clin Exp Res, vol.34, pp.1849-57, 2010. ,
Baclofen as add-on to standard psychosocial treatment for alcohol dependence: a randomized, double-blind, placebo-controlled trial with 1 year follow-up, J Subst Abuse Treat, vol.52, pp.24-30, 2015. ,
,
, Zh Nevrol
, , vol.115, pp.53-62, 2015.
Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebocontrolled trial, Alcohol Alcohol, vol.46, pp.312-319, 2011. ,
The doseeffect relationship of baclofen in alcohol dependence: a 1-year cohort study, Hum Psychopharmacol Clin Exp, p.32, 2017. ,
Suppression of alcohol dependence using baclofen: a 2-year observational study of 100 patients, Front Psychiatry, vol.3, p.103, 2012. ,
High-dose baclofen for treatmentresistant alcohol dependence, J Clin Psychopharmacol, vol.32, pp.266-274, 2012. ,
Abstinence and "low-risk" consumption 1 year after the initiation of high-dose baclofen: a retrospective study among "high-risk" drinkers, Alcohol Alcohol, vol.47, pp.439-481, 2012. ,
Alcohol-dependence: the current French craze for baclofen, Addiction, vol.107, pp.848-857, 2012. ,
Pharmacotherapy for alcohol dependence: the 2015 recommendations of the French alcohol society, issued in partnership with the European Federation of Addiction Societies, CNS Neurosci Ther, vol.22, pp.25-37, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01276028
Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: a multicentre, randomised, double-blind controlled trial, Eur Neuropsychopharmacol, vol.26, pp.1950-1959, 2016. ,
A randomized, placebo-controlled study of high-dose baclofen in alcoholdependent patients-the ALPADIR study, Alcohol Alcohol, vol.52, pp.439-485, 2017. ,
Baclofen for alcohol dependence: relationships between baclofen and alcohol dosing and the occurrence of major sedation, Eur Neuropsychopharmacol, vol.25, pp.1631-1637, 2015. ,
Proactive regional pharmacovigilance system versus national spontaneous reporting for collecting safety data on concerning off-label prescribing practices: an example with baclofen and alcohol dependence in France, Drug Saf, vol.40, pp.257-62, 2017. ,
High variability in the exposure of baclofen in alcohol-dependent patients, Alcohol Clin Exp Res, vol.38, pp.316-337, 2014. ,
Anticraving effect of baclofen in alcohol-dependent patients, Alcohol Clin Exp Res, vol.39, pp.1602-1610, 2015. ,
NONMEM User's Guides. Icon Development Solutions, 2009. ,
Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods, CPT pharmacometrics Syst Pharmacol, vol.2, p.38, 2013. ,
Basic concepts in population modeling, simulation, and model-based drug development, CPT pharmacometrics Syst. Pharmacol, vol.1, p.6, 2012. ,
Basic concepts in population modeling, simulation, and model-based drug development: part 3-introduction to pharmacodynamic modeling methods, CPT pharmacometrics Syst Pharmacol, vol.3, p.88, 2014. ,
Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide, Pharm Res, vol.23, pp.2036-2085, 2006. ,
URL : https://hal.archives-ouvertes.fr/inserm-00189557
Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients, J Pharmacokinet Biopharm, vol.26, pp.207-253, 1998. ,
Highdose baclofen for the treatment of alcohol dependence (BACLAD study): a randomized, placebo-controlled trial, Eur Neuropsychopharmacol, vol.25, pp.1167-77, 2015. ,
Safety challenges of using high dose baclofen for alcohol use disorder: a focused review, Front Psychiatry, vol.9, p.367, 2018. ,
URL : https://hal.archives-ouvertes.fr/inserm-01969917
Baclofen toxicity in a patient with the hemodialysis-dependent end-stage renal disease, J Emerg Med, vol.52, pp.99-100, 2017. ,
High doses of Baclofen as suicide attempt in patients with alcohol use disorders-a serious concern, Asian J Psychiatry, vol.17, pp.99-100, 2015. ,
Safety and drinking outcomes among patients with comorbid alcohol dependence and borderline personality disorder treated with high-dose baclofen: a comparative cohort study, Int Clin Psychopharmacol, vol.30, pp.49-53, 2015. ,
Self-intoxication with baclofen in alcohol-dependent patients with co-existing psychiatric illness: an emergency department case series, Alcohol Alcohol, vol.49, pp.79-83, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-01917064
Safety reports on the offlabel use of baclofen for alcohol-dependence: recommendations to improve causality assessment, Expert Opin Drug Saf, vol.15, pp.747-51, 2016. ,